The Week

ArriVent Biopharma (AVBP) fell 40.82% this week to close at $16.73. The stock swung hard, from Monday’s modest close near prior levels to Monday’s high of $28.70, then a Tuesday gap down that drove price to an intraday low of $11.36, marking a new 52-week low. It stabilised into Wednesday, Thursday and Friday, holding between $16.49 and $17.76. Weekly volume reached 28.47m shares, with average daily turnover of about 5.69m shares, well above the 60-day median and concentrated around the event window.

Key Events

The week centred on the Phase 3 FURVENT trial update late on 6 October. ArriVent said firmonertinib in first-line EGFR exon 20 insertion non-small cell lung cancer missed its primary progression-free survival endpoint. The stock reacted with a sharp sell-off, briefly down more than 58% and touching a 12-month low, according to several market snapshots. Around the same time, law firms issued notices related to potential securities claims involving AVBP. In the days that followed, several brokers kept buy ratings while trimming price targets to $15, $22, $27 and $29, citing upside from the broader pipeline and upcoming ADC data.

Analyst Ratings

Eleven analysts cover AVBP. Eleven rate it buy, with no over, hold, under or sell ratings. The consensus recommendation is strong buy. The consensus target price is about $20.56, roughly 22.87% above the latest price of $16.73. Individual targets range from $15.00 to $29.00, showing a wide spread. Within the biotechnology industry, AVBP ranks 122nd out of 508 names by analyst rating.

The Week Ahead

The macro calendar is quiet on company-specific catalysts but denser on US data. Tuesday 13 October brings NFIB small-business sentiment and existing-home sales annualised, with forecasts at 3.96m versus a prior 3.98m. Wednesday 14 October features US CPI and core CPI: headline CPI is forecast at 3.7% versus a prior 3.4%, while core CPI is forecast at 2.5% versus 2.4%. For AVBP itself, follow-ups from shareholder investigations or new clinical data could shape whether the stock holds current levels.

In Short

ArriVent fell to a 52-week low after the Phase 3 trial missed its main endpoint, with shareholder inquiries adding legal overhang. Yet the sell-side cohort remains strong buy, and the consensus target sits above the spot price, reflecting expectations for the broader pipeline. In the latest trading day, large-lot money showed net inflows while retail money showed net outflows, pointing to split positioning. Whether the stock can regain ground will depend on new clinical catalysts such as ADC data and whether legal risks further compress valuations.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.